Artelo Biosciences Inc (ARTL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Artelo Biosciences Inc (ARTL) has a cash flow conversion efficiency ratio of 3.342x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.25 Million) by net assets ($-1.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Artelo Biosciences Inc balance sheet quality to measure how much of total assets are equity-financed.
Artelo Biosciences Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Artelo Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore ARTL long-term investment intensity to see how much of total assets are deployed in long-term investments.
Artelo Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Artelo Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tijaria Polypipes Limited
NSE:TIJARIA
|
-0.154x |
|
Surya Oil & Gas Corp.
NASDAQ:SURY
|
0.011x |
|
Oncternal Therapeutics Inc
NASDAQ:ONCT
|
-0.760x |
|
Trufin PLC
LSE:TRU
|
0.076x |
|
Goobit Group AB
ST:BTCX
|
0.705x |
|
Golden Cross Resources Ltd
AU:GCR
|
-0.046x |
|
Castings PLC
LSE:CGS
|
0.124x |
|
Hynion AS
OL:HYN
|
0.061x |
Annual Cash Flow Conversion Efficiency for Artelo Biosciences Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Artelo Biosciences Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Artelo Biosciences Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-1.27 Million | $-8.52 Million | 6.698x | +329.18% |
| 2024-12-31 | $2.86 Million | $-8.35 Million | -2.923x | -318.51% |
| 2023-12-31 | $11.75 Million | $-8.21 Million | -0.698x | -69.21% |
| 2022-12-31 | $19.40 Million | $-8.01 Million | -0.413x | +19.07% |
| 2021-12-31 | $12.04 Million | $-6.14 Million | -0.510x | +54.55% |
| 2020-12-31 | $3.87 Million | $-4.35 Million | -1.122x | -119.41% |
| 2019-12-31 | $5.46 Million | $-2.79 Million | -0.511x | -104.29% |
| 2018-12-31 | $-134.97K | $-1.61 Million | 11.928x | +3097.41% |
| 2017-12-31 | $544.84K | $-216.82K | -0.398x | -129.70% |
| 2016-12-31 | $-13.80K | $-18.49K | 1.340x | +251.72% |
| 2015-12-31 | $15.29K | $-13.50K | -0.883x | -70.39% |
| 2014-12-31 | $29.46K | $-15.27K | -0.518x | -- |
About Artelo Biosciences Inc
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a coc… Read more